Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jochem W van Werkum

Showing results (11-20 of 36) with videos related to

Pageof 4
Sort By:
Future Cardiology|October 7, 2009
Monitoring antiplatelet therapy with point-of-care platelet function assays: a review of the evidenceJochem W van Werkum, Christian M Hackeng, Jaap-Jan J Smit, et al.
International Journal of Cardiology|December 19, 2008
A comparison between the Plateletworks-assay and light transmittance aggregometry for monitoring the inhibitory effects of clopidogrelJochem W van Werkum, Marjolein Kleibeuker, Sonja Postma, et al.
Platelets|November 26, 2009
Vigorous exercise as a triggering mechanism for late stent thrombosis: A description of three casesBastiaan Zwart, Tjitske C Van Kerkvoorde, Jochem W van Werkum, et al.
Heart (British Cardiac Society)|April 12, 2011
High on-treatment platelet reactivity to both aspirin and clopidogrel is associated with the highest risk of adverse events following percutaneous coronary interventionNicoline J Breet, Jochem W van Werkum, Heleen J Bouman, et al.
Journal of Electrocardiology|August 30, 2011
Predictors and outcome of grade 3 ischemia in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary interventionSonja Postma, Ton Heestermans, Jurrien W Ten Berg, et al.
International Journal of Cardiology|August 4, 2007
Staphylococcus aureus infection complicating percutaneous coronary interventionsJochem W van Werkum, Jurriën M ten Berg, H W Thijs Plokker, et al.
Nature Medicine|December 21, 2010
Paraoxonase-1 is a major determinant of clopidogrel efficacyHeleen J Bouman, Edgar Schömig, Jochem W van Werkum, et al.
Platelets|December 15, 2010
Sulfonylureas and on-clopidogrel platelet reactivity in type 2 diabetes mellitus patientsAnkie M Harmsze, Jochem W Van Werkum, Fulya Moral, et al.
Heart (British Cardiac Society)|October 5, 2010
Prehospital triple antiplatelet therapy in patients with acute ST elevation myocardial infarction leads to better platelet aggregation inhibition and clinical outcome than dual antiplatelet therapyJaap Jan J Smit, Jochem W van Werkum, Jurrien ten Berg, et al.
Heart (British Cardiac Society)|June 2, 2011
Variability in on-treatment platelet reactivity explained by CYP2C19*2 genotype is modest in clopidogrel pretreated patients undergoing coronary stentingHeleen J Bouman, Ankie M Harmsze, Jochem W van Werkum, et al.
Pageof 4

Showing results (11-20 of 36) with videos related to

Sort By:
Pageof 4
Future Cardiology|October 7, 2009
Monitoring antiplatelet therapy with point-of-care platelet function assays: a review of the evidenceJochem W van Werkum, Christian M Hackeng, Jaap-Jan J Smit, et al.
International Journal of Cardiology|December 19, 2008
A comparison between the Plateletworks-assay and light transmittance aggregometry for monitoring the inhibitory effects of clopidogrelJochem W van Werkum, Marjolein Kleibeuker, Sonja Postma, et al.
Platelets|November 26, 2009
Vigorous exercise as a triggering mechanism for late stent thrombosis: A description of three casesBastiaan Zwart, Tjitske C Van Kerkvoorde, Jochem W van Werkum, et al.
Heart (British Cardiac Society)|April 12, 2011
High on-treatment platelet reactivity to both aspirin and clopidogrel is associated with the highest risk of adverse events following percutaneous coronary interventionNicoline J Breet, Jochem W van Werkum, Heleen J Bouman, et al.
Journal of Electrocardiology|August 30, 2011
Predictors and outcome of grade 3 ischemia in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary interventionSonja Postma, Ton Heestermans, Jurrien W Ten Berg, et al.
International Journal of Cardiology|August 4, 2007
Staphylococcus aureus infection complicating percutaneous coronary interventionsJochem W van Werkum, Jurriën M ten Berg, H W Thijs Plokker, et al.
Nature Medicine|December 21, 2010
Paraoxonase-1 is a major determinant of clopidogrel efficacyHeleen J Bouman, Edgar Schömig, Jochem W van Werkum, et al.
Platelets|December 15, 2010
Sulfonylureas and on-clopidogrel platelet reactivity in type 2 diabetes mellitus patientsAnkie M Harmsze, Jochem W Van Werkum, Fulya Moral, et al.
Heart (British Cardiac Society)|October 5, 2010
Prehospital triple antiplatelet therapy in patients with acute ST elevation myocardial infarction leads to better platelet aggregation inhibition and clinical outcome than dual antiplatelet therapyJaap Jan J Smit, Jochem W van Werkum, Jurrien ten Berg, et al.
Heart (British Cardiac Society)|June 2, 2011
Variability in on-treatment platelet reactivity explained by CYP2C19*2 genotype is modest in clopidogrel pretreated patients undergoing coronary stentingHeleen J Bouman, Ankie M Harmsze, Jochem W van Werkum, et al.
Pageof 4